Welcome to Trends-in-Medicine, offering independent, cutting-edge articles and information on drugs and devices in development. Our subscribers have access to news and analysis on the latest data, regulatory issues, and trends of interest to the healthcare community.

American Academy of Dermatology VMX: Psoriasis Update

There was a wealth of new data at the AAD VMX meeting, particularly on psoriasis drugs – one that is approved and 5 that are still investigational. Each of those investigational drugs is from a different company and has a different mode of action – a PDE4 inhibitor, an anti-IL-36, a TYK2 inhibitor, an AhR modulator, and an anti-IL-17A/F.

ACIP Update

After a review, CDC’s ACIP agreed with the FDA that Pfizer’s Covid-19 vaccine is appropriate for adolescents. The panel also reiterated its belief in the safety of the Johnson & Johnson vaccine, despite blood clots that are not seen with the mRNA vaccines, and reviewed the status of variants.

ACIP tells FDA/CDC: Continue the Pause on the J&J Covid-19 Vaccine

One day after the CDC and the FDA recommended a voluntary “pause” in the use of Johnson & Johnson/Janssen’s Ad26.COV2.S (JNJ-78436735), a Covid-19 vaccine, the Centers for Disease Control and Prevention (CDC)’s Advisory Committee on Immunization Practices (ACIP) met and said it needs more data, additional risk refinement, and a benefit:risk assessment before it can make a decision on what should be done ab out the vaccine. That meeting is now scheduled for April 23, 2021.

Use of J&J's Covid-19 Vaccine "Paused"

The Centers for Disease Control and Prevention (CDC) and the FDA recommended a “pause” in the use of Johnson & Johnson/Janssen’s Covid-19 vaccine, Ad26.COV2.S (JNJ-78436735), after six reported cases in the U.S. of a “severe stroke-like illness” linked to a rare type of blood clot. One patient died. Here is what you need to know.

ENDO 2021

Rare endocrine diseases, often manifesting in childhood or even infancy – but even extending into adulthood for some conditions – are getting attention from researchers who are developing targeted therapies in hopes of correcting or reversing the endocrine abnormalities created by congenital or inherited genetic conditions. At the virtual 2021 meeting of the Endocrine Society, researchers reported on ongoing treatments that could make big differences in the lives of these patients, including new agents for hypoparathyroidism, obesity, growth hormone deficiency, achondroplasia, and acromegaly.

ESMO-TAT Congress -- Drugs to Watch

ESMO’s TAT Congress offered a glimpse into three early-stage targeted therapies: Spectrum Pharmaceuticals’ poziotinib – efficacy still a question and BID dosing only marginally improves tolerability; Black Diamond Therapeutics’ BDTX – much too early to know much but an interesting idea; and Bristol-Myers Squibb’s CC-90010 – a hint of efficacy and no significant food effect.

What was Learned in the CDC Review of the J&J Covid-19 Vaccine

Johnson & Johnson’s Ad26.COV2.S is the latest Covid-19 vaccine to become available in the U.S. CDC’s ACIP review of the vaccine brought out a number of points, raised some questions, and provided a few answers that you may not have heard before about that vaccine.